08 June 2018 : Laboratory Research
Upregulation of KIF26B, Cell Migration and Proliferation of Human Ovarian Cancer Cell Lines In Vitro, and Patient Outcomes from Human Bioinformatic Analysis
Xingshuang Yang1BCDE, Lan Zhang2ABCDE, Lei Xie3ABCDEF*DOI: 10.12659/MSM.907889
Med Sci Monit 2018; 24: LBR3863-3872
Abstract
BACKGROUND: The aim of this study was to assess the expression profile of the KIF26B gene, its effects on ovarian cancer cell behavior in vitro, the clinical prognostic value of expression of the KIF26B gene and associated signaling pathways, from bioinformatics data analysis.
MATERIAL AND METHODS: The Cancer Genome Atlas-Ovarian Cancer (TCGA-OV) database and the online Kaplan-Meier plotter for ovarian cancer were analyzed. Human ovarian cancer cell lines A2780 and SKOV3 were used to study the in vitro effects of KIF26B gene expression on cell proliferation and cell invasion. Genes that interacted with, co-localized to, and were co-expressed with the KIF26B gene (Pearson’s r ≥0.6) were identified and underwent Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
RESULTS: Increased expression of the KIF26B gene increased the proliferation and migration of A2780 and SKOV3 cells in vitro. KIF26B protein expression was upregulated in ovarian cancer tissue and was associated with lymphatic and venous invasion. TCGA-OV data analysis showed that increased expression of the KIF26B gene was significantly associated with reduced 3-year, 5-year, and 10-year overall survival (OS), progression-free survival (PFS), and post-progression survival (PPS). The genes that interacted with, co-localized to, and were co-expressed with KIF26B were enriched in several KEGG pathways; upregulation of the KIF26B gene was associated with TGF-β signaling pathway.
CONCLUSIONS: Upregulation of KIF26B enhanced proliferation and migration of ovarian cancer cells in vitro. Bioinformatics analysis supported the association between increased expression of the KIF26B gene and reduced clinical outcome in patients with ovarian carcinoma.
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952